Format

Send to

Choose Destination
Nephron. 2017;136(2):137-142. doi: 10.1159/000455289. Epub 2017 Feb 10.

Why Current PTH Assays Mislead Clinical Decision Making in Patients with Secondary Hyperparathyroidism.

Author information

1
Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.

Abstract

Preclinical studies in cell culture systems as well as in whole animal chronic kidney disease (CKD) models showed that parathyroid hormone (PTH), oxidized at the 2 methionine residues (positions 8 and 18), caused a loss of function. This was so far not considered in the development of PTH assays used in current clinical practice. Patients with advanced CKD are subject to oxidative stress, and plasma proteins (including PTH) are targets for oxidants. In patients with CKD, a considerable but variable fraction (about 70 to 90%) of measured PTH appears to be oxidized. Oxidized PTH (oxPTH) does not interact with the PTH receptor resulting in loss of biological activity. Currently used intact PTH (iPTH) assays detect both oxidized and non-oxPTH (n-oxPTH). Clinical studies demonstrated that bioactive, n-oxPTH, but not iPTH nor oxPTH, is associated with mortality in CKD patients.

KEYWORDS:

Dialysis patients ; Mortality; Serum intact-parathyroid hormone level

PMID:
28183082
DOI:
10.1159/000455289
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center